Exchange Capital Management Inc. Has $1.33 Million Stock Position in Eli Lilly and Company $LLY

Exchange Capital Management Inc. lowered its holdings in shares of Eli Lilly and Company (NYSE:LLY) by 5.8% in the 2nd quarter, Holdings Channel.com reports. The fund owned 1,702 shares of the company’s stock after selling 105 shares during the period. Exchange Capital Management Inc.’s holdings in Eli Lilly and Company were worth $1,326,000 at the end of the most recent quarter.

Several other institutional investors also recently modified their holdings of the business. Brighton Jones LLC raised its position in shares of Eli Lilly and Company by 22.0% during the fourth quarter. Brighton Jones LLC now owns 9,597 shares of the company’s stock worth $7,409,000 after acquiring an additional 1,730 shares during the last quarter. Revolve Wealth Partners LLC boosted its holdings in Eli Lilly and Company by 2.8% in the fourth quarter. Revolve Wealth Partners LLC now owns 1,471 shares of the company’s stock valued at $1,136,000 after acquiring an additional 40 shares during the last quarter. Apella Capital LLC raised its holdings in Eli Lilly and Company by 9.4% during the 1st quarter. Apella Capital LLC now owns 1,749 shares of the company’s stock worth $1,318,000 after purchasing an additional 151 shares during the last quarter. Iams Wealth Management LLC lifted its position in shares of Eli Lilly and Company by 13.9% in the 1st quarter. Iams Wealth Management LLC now owns 368 shares of the company’s stock worth $304,000 after purchasing an additional 45 shares during the period. Finally, Clare Market Investments LLC boosted its stake in shares of Eli Lilly and Company by 90.8% in the 1st quarter. Clare Market Investments LLC now owns 4,209 shares of the company’s stock valued at $3,476,000 after purchasing an additional 2,003 shares during the last quarter. Institutional investors own 82.53% of the company’s stock.

Analyst Ratings Changes

A number of equities analysts recently weighed in on the stock. Erste Group Bank downgraded shares of Eli Lilly and Company from a “buy” rating to a “hold” rating in a research note on Thursday, June 5th. Guggenheim lowered their price objective on Eli Lilly and Company from $942.00 to $875.00 and set a “buy” rating for the company in a research report on Wednesday, August 13th. Cantor Fitzgerald cut their target price on Eli Lilly and Company from $975.00 to $825.00 and set an “overweight” rating on the stock in a research report on Wednesday, August 13th. Leerink Partners reaffirmed a “market perform” rating and set a $715.00 target price on shares of Eli Lilly and Company in a research note on Thursday, August 7th. Finally, DZ Bank raised Eli Lilly and Company from a “hold” rating to a “strong-buy” rating in a research note on Thursday, August 14th. One research analyst has rated the stock with a Strong Buy rating, fourteen have issued a Buy rating and nine have assigned a Hold rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $939.61.

Eli Lilly and Company Trading Down 0.6%

Shares of Eli Lilly and Company stock opened at $820.69 on Friday. The company has a debt-to-equity ratio of 1.86, a quick ratio of 1.00 and a current ratio of 1.28. Eli Lilly and Company has a 52 week low of $623.78 and a 52 week high of $937.00. The stock has a 50 day moving average price of $734.03 and a two-hundred day moving average price of $766.34. The stock has a market capitalization of $776.75 billion, a PE ratio of 53.64, a price-to-earnings-growth ratio of 1.15 and a beta of 0.47.

Eli Lilly and Company (NYSE:LLY) last issued its earnings results on Thursday, August 7th. The company reported $6.31 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $5.59 by $0.72. Eli Lilly and Company had a return on equity of 92.72% and a net margin of 25.91%.The company had revenue of $15.56 billion for the quarter, compared to analysts’ expectations of $14.40 billion. During the same period last year, the business earned $3.92 EPS. Eli Lilly and Company’s quarterly revenue was up 37.6% compared to the same quarter last year. Eli Lilly and Company has set its FY 2025 guidance at 21.750-23.000 EPS. As a group, equities analysts anticipate that Eli Lilly and Company will post 23.48 earnings per share for the current fiscal year.

Insider Transactions at Eli Lilly and Company

In other Eli Lilly and Company news, CEO David A. Ricks acquired 1,632 shares of Eli Lilly and Company stock in a transaction dated Tuesday, August 12th. The stock was purchased at an average cost of $644.77 per share, for a total transaction of $1,052,264.64. Following the completion of the acquisition, the chief executive officer directly owned 546,601 shares of the company’s stock, valued at $352,431,926.77. This represents a 0.30% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, Director Gabrielle Sulzberger bought 117 shares of the stock in a transaction that occurred on Tuesday, August 12th. The stock was acquired at an average price of $641.18 per share, for a total transaction of $75,018.06. Following the acquisition, the director directly owned 2,703 shares in the company, valued at $1,733,109.54. The trade was a 4.52% increase in their ownership of the stock. The disclosure for this purchase can be found here. In the last three months, insiders purchased 4,514 shares of company stock valued at $2,894,841. Corporate insiders own 0.13% of the company’s stock.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.